



NDA 21636/S009
NDA 21849/S004
NDA 21850/S003
NDA 22456/S002

SUPPLEMENT APPROVAL

Santarus, Inc.
Attention: Maria Bedoya-Toro, Ph.D.
Vice President, Regulatory Affairs and Quality Assurance
3721 Valley Center Drive, Suite 400
San Diego, CA 92130

Dear Dr. Bedoya-Toro:

Please refer to your supplemental new drug applications dated July 21, 2010 and received July 22, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zegerid (omeprazole/sodium bicarbonate) Powder for Oral Suspension, Zegerid (omeprazole/sodium bicarbonate) Capsules, Zegerid with Magnesium Hydroxide (omeprazole/sodium bicarbonate/magnesium hydroxide) Chewable Tablets; and Omeprazole/sodium bicarbonate/magnesium hydroxide Tablets.

We acknowledge receipt of your submissions dated August 18, August 31, and September 2, 2010.

Reference is also made to our letter dated May 25, 2010 notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for the proton pump inhibitors (PPIs). This information pertains to the risk of osteoporosis-related bone fractures in patients taking proton pump inhibitors for an extended period of time and at high doses.

This supplemental new drug application provides for revisions to the full prescribing information and patient labeling for Zegerid. This includes the following addition to the Warnings and Precautions section:

WARNINGS AND PRECAUTIONS:

Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines. [See Dosage and Administration (2) and Adverse Reactions (6.2)]

In addition, this supplemental new drug application provides for revised language regarding bone fractures to the **Highlights, Table of Contents, Adverse Reactions, and Patient Counseling Information** including FDA-Approved Patient Labeling sections of the package insert.

We have completed our review of this supplemental application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. The SPL will be accessible from publicly available labeling repositories.

We request that the revised labeling approved today be available on your website within 10 days of receipt of this letter.

Also within 14 days, amend all pending supplemental applications for this NDA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

If you have any questions, call Maureen Dewey, at (301) 796-0845.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22456	SUPPL-2	SANTARUS INC	ZEGERID
NDA-21849	SUPPL-4	SANTARUS INC	ZEGERID (OMEPRAZOLE) 20/40 MG CAPSULE
NDA-21636	SUPPL-9	SANTARUS INC	ZEGERID

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
09/03/2010